Cancer clinical trials in the region Bretagne

256 currently recruiting clinical trials
Region Bretagne

Phase 3 Lung cancer #NCT07195695 #2025-521284-12-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Localized
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK EGFR
Excluded previous treatments at localized stage
Radiotherapy
6 recruiting sites
Boehringer Ingelheim
Phase 3 Ovarian / Fallopian tubes / Peritoneum cancer #NCT06476184 #2023-508260-30-01
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC) Endometrioid carcinoma Other epithelial ovarian cancer
Required FIGO stages
Stage III Stage IV
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
35 recruiting sites
ARCAGY/ GINECO GROUP
Phase 3 Lung cancer #NCT06890598 #2024-512302-25-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Required genetic anomalies
KRAS G12C
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Chemotherapy Radiotherapy
Excluded genetic anomalies
ALK EGFR
14 recruiting sites
Eli Lilly et compagnie
Phase 3 Lung cancer #NCT06890598 #2024-512302-25-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Localized Locally Advanced
Required genetic anomalies
KRAS G12C
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Surgery Immunotherapy Chemotherapy
Excluded genetic anomalies
ALK EGFR
14 recruiting sites
Eli Lilly et compagnie
Phase 3 Breast cancer #NCT05633654
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery Chemotherapy Radiotherapy
Required previous treatments at advanced or metastatic stage
Surgery Chemotherapy Radiotherapy
Excluded genetic anomalies
BRCA 1/2
Excluded previous treatments at localized stage
Systemic Treatment-Naive Immunotherapy Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Immunotherapy Antibody Drug Conjugates (ADC)
15 recruiting sites
Gilead Sciences
Phase 3 Prostate cancer #NCT07028853 #2024-519369-24-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Hormone-sensitive
Required number of previous lines of therapy for current stage of disease
None
Excluded previous treatments at advanced or metastatic stage
Chemotherapy
11 recruiting sites
Pfizer
Phase 3 Lung cancer #NCT06801834 #2024-515884-69-00
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
12 recruiting sites
Gilead Sciences
Phase 3 Cervical / Vulvar / Vaginal cancer #NCT05581121
Required histologic types
Cervical cancer
Required histologic sub types
Squamous cell carcinoma Adenocarcinoma Adenosquamous carcinoma
Required FIGO stages
Stage III
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Radiotherapy
Excluded previous treatments at advanced or metastatic stage
Radiotherapy
24 recruiting sites
Institut Claudius Regaud
Phase 3 Cervical / Vulvar / Vaginal cancer #NCT05078047
Required histologic types
Cervical cancer
Required disease stage
Locally Advanced Metastatic
25 recruiting sites
UNICANCER
Phase 3 Head and neck cancer #NCT04892173
Required histologic types
Oral cavity Oropharynx Hypopharynx Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Surgery Chemotherapy Radiotherapy Radiochemotherapy
15 recruiting sites
Johnson & Johnson Enterprise Innovation Inc.